Cryoport, Inc., a global provider of products and services to the cell and gene therapy industry, has acquired Tec4med Lifescience GmbH, a solution provider in the pharmaceutical supply chain visibility, condition monitoring and temperature-controlled packaging space.

Tec4med provides next generation pharmaceutical supply chain visibility by integrating condition monitoring, cloud, and artificial intelligence (AI) solutions. ISO 9001-certified, Tec4med works with pharmaceutical-compliant, ready-to-use devices and intuitive easy-to-use software, offering customer-specific integrations to meet client needs. Tec4med will continue to be run by the current management team.

“The acquisition of Tec4med is an important step for us in broadening our portfolio of condition monitoring solutions, fostering new product development and accelerating European market expansion, particularly in the DACH region (Germany, Austria, Switzerland),” said Jerrell Shelton, CEO of Cryoport. “By integrating Tec4med’s innovative solutions and services across Cryoport’s family of companies, we will also expand our digital supply chain solutions offerings for the life sciences industry and provide our global clients even greater condition monitoring system options, logistics management capabilities and customer support.”

Mark Sawicki, CEO of Cryoport Systems said, “The biopharmaceutical industry loses approximately $35 billion annually as a result of failures in temperature-controlled logistics. Adding Tec4med’s technology and project-based expertise will enhance Cryoport’s end-to-end supply chain solutions — including advanced real-time condition monitoring — and drive its digitization to provide our customers with full transparency within the pharmaceutical supply chain The Tec4med technology services will supplement and complement Cryoport’s existing services, bolstering the seamless integration of condition monitoring hardware and software throughout our solutions portfolio.”